an update on the safety and efficacy of rusfertide in polycythemia vera
Published 1 year ago • 270 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
1:56
rationale for verify: rusfertide added to ongoing therapy in patients with polycythemia vera
-
2:08
phase iii trial of rusfertide in patients with polycythemia vera
-
3:07
the current treatment algorithm for polycythemia vera
-
3:10
promising trials in polycythemia vera
-
5:50
machine-learning to predict hydroxyurea failure & thromboembolic events in polycythemia vera
-
1:04
promising agents under investigation in polycythemia vera
-
1:39
upcoming agents in et and pv
-
6:49
the role of interferon in polycythemia vera & perspectives on the management of low-risk patients
-
10:56
identifying and communicating your polycythemia vera (pv) symptoms
-
6:01
common signs and symptoms of polycythemia vera
-
6:24
polycythemia vera: latest updates for patients & caregivers in 2022 | dr. ruben mesa | blood cancer
-
2:38
ongoing data from the phase 3 response trial of ruxolitinib for polycythemia vera
-
3:19
targeting jak2 v617f vaf in polycythemia vera & the efficacy of ropeginterferon alfa-2b
-
1:52
safety and efficacy of idasanutlin in pv
-
1:42
unmet needs in the polycythemia vera and essential thrombocythemia
-
9:07
revive: targeted therapy for uncontrolled erythrocytosis in pv with rusfertide
-
2:16
ropeginterferon vs standard therapy for polycythemia vera
-
2:14
risk-adapted treatment of et & pv
-
5:56
rusfertide reduces need for therapeutic phlebotomy in pv patients
-
3:16
the importance of early intervention in young patients with mpns & the role of interferon therapy
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
3:08
reveal: association between elevated blood counts and thrombotic events in polycythemia vera